Navigation Links
Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
Date:2/14/2011

ing body of evidence supporting the drug's antiviral activity in humans.  

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses.  The Open-Label Study builds on Chimerix's extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs.  CMX001 has been well tolerated in all studies.

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release.  Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases.

Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies.  Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses.  A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.  

<
'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
2. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
3. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
4. Chimerix to Present at Upcoming Investor Conferences
5. Chimerix Initiates Phase 1 Study of CMX157
6. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
7. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
8. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
9. Chimerix Joins International Network of Organizations to Cure Malaria
10. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
11. Cognition Therapeutics Completes $2.5M in Series A1 Financing to Advance Alzheimers Disease Drug Treatment Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 Philadelphia’s newest entrepreneurial incubation space ... their start. The Innovation Center @3401 , a collaborative ... City Science Center to help attract and nurture start-up ... July 28. , The Innovation Center @3401 ... Market Streets, is the new home of DreamIt Ventures ...
(Date:7/29/2014)... -- United Therapeutics Corporation (NASDAQ: UTHR ... the second quarter ended June 30, 2014. ... medicines are reaching increasing numbers of patients ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... quarter of our extended-release tablet called Orenitram ...
(Date:7/29/2014)... Wendel – recipient of a Regional Top Doctor Award for ... Surgeon Specialists for Nashville, TN – has released a new ... Hydration Booster, Retexturing Night Crème, and Anti-aging C Complex, all ... radiant appearance while protecting them from the sun’s harmful UV ... Dr. J. J. Wendel Plastic Surgery, we have developed a ...
(Date:7/28/2014)... July 28, 2014 Sapphire Energy, Inc. ... announced the appointment of biotechnology veteran James Levine ... of directors. Levine replaces Cynthia ,CJ, Warner, who is ... remain chairman of the company,s board of directors. ... mission to deliver commercial scale algae-based fuels has been ...
Breaking Biology Technology:Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Dr. J. J. Wendel Launches New Line of Skin Care Products 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3
... like when it was a baby. They know what it ... looked in its youth. Thanks to technological advances, however, scientists ... of how the cosmos developed into the kind of place ... They plan to gather these never-before-obtained insights with a potentially ...
... BOTHELL, Wash., June 30, 2011 SCOLR Pharma, Inc. ... second and final tranche of its previously-announced private placement ... (the "Debentures").  The Company raised a total of $1,190,200 ... net proceeds for working capital and other general corporate ...
... OXIS International, Inc. (OTC Bulletin Board: OXIS ; ... Saloff to its Board of Directors.  The Company,s Board now ... are very pleased to have David Saloff, an outstanding businessmen ... said Anthony J. Cataldo, Chairman of OXIS International. "OXIS is ...
Cached Biology Technology:Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 2Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 3Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 4SCOLR Pharma, Inc. Announces Final Closing of Private Placement 2SCOLR Pharma, Inc. Announces Final Closing of Private Placement 3OXIS International Names Healthcare Industry Entrepreneur David Saloff to Board of Directors 2OXIS International Names Healthcare Industry Entrepreneur David Saloff to Board of Directors 3
(Date:7/28/2014)... 100 drugs already approved by the U.S. Food and ... the growth of certain bacterial pathogens inside human cells, ... spotted fever. The findings, published in mBio , ... Microbiology, demonstrate a new way of identifying non-antibiotic drugs ... , A handful of drugs on the list inhibit ...
(Date:7/28/2014)... reached the South Pole in 1911, but new research ... human. , Using data from 16 ice cores collected ... the South Pole, a group led by Joe McConnell ... created the most accurate and precise reconstruction to date ... record, described in an article published today in the ...
(Date:7/28/2014)... in the United States have a circulatory problem of ... painful and may even require surgery in serious cases. ... and, in turn, limb amputation. , At The University ... School, scientists tested a non-surgical preventative treatment in a ... with increased blood circulation. Their proof-of-concept study appears ...
Breaking Biology News(10 mins):New route to identify drugs that can fight bacterial infections 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... American Academy of Pediatrics National Children,s Art Contest drew hundreds ... With the theme of "My Healthy Lifestyle," the 2011 ... obesity, diet, exercise, sleep and limiting screen time. This was ... of the three age groups each receive a $500 cash ...
... grown apple may hold within it a tiny bit of ... teamed up on a startup that promises to turn slash ... for farmers that helps their soil hold water and nutrients. ... for farmers. "Wine growers, organic farmers and gardeners of all ...
... generally considered to be a good thing for people ... too risky for women who are also pregnant. Some ... the risk of women developing preeclampsia, a condition that ... this might happen has remained unknown. New research using ...
Cached Biology News:Turning slash piles into soil benefit 2Exercise before and during early pregnancy increases two beneficial proteins for mothers-to-be 2